Drug Search Results
More Filters [+]


Alternative Names: carbinoxamine, karbinal er, clistin, ryvent
Latest Update: None
Latest Update Note: None

Product Description

Mechanisms of Action: H1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Approved

Approved Countries: Brazil | Chile | Cyprus | Egypt | Hong Kong | India | Ireland | Italy | Jordan | Korea | Lebanon | Malaysia | Mexico | Pakistan | Peru | South Africa | Taiwan | United Arab Emirates | United States | Venezuela

Approved Indications: Angioedema | Urticaria | Oral Manifestations | Conjunctivitis | Conjunctivitis, Allergic | Rhinitis | Rhinitis, Allergic | Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Seasonal | Rhinitis, Vasomotor | Edema | Skin Manifestations

Known Adverse Events: Generalized anxiety disorder | Dizziness

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Carbinoxamine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events